Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Preferred Stock Liabilities: 2019-2020

  • C4 Therapeutics' Preferred Stock Liabilities rose 133.21% to $256.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $256.5 million, marking a year-over-year increase of 133.21%. This contributed to the annual value of $111.0 million for FY2019, which is N/A change from last year.
  • C4 Therapeutics' Preferred Stock Liabilities amounted to $256.5 million in Q3 2020, which was up 131.11% from $111.0 million recorded in Q4 2019.
  • C4 Therapeutics' Preferred Stock Liabilities' 5-year high stood at $256.5 million during Q3 2020, with a 5-year trough of $110.0 million in Q3 2019.
  • Moreover, its 2-year median value for Preferred Stock Liabilities was $111.0 million (2019), whereas its average is $159.2 million.
  • Data for C4 Therapeutics' Preferred Stock Liabilities shows a peak YoY surged of 133.21% (in 2020) over the last 5 years.
  • Over the past 2 years, C4 Therapeutics' Preferred Stock Liabilities (Quarterly) stood at $111.0 million in 2019, then spiked by 133.21% to $256.5 million in 2020.
  • Its Preferred Stock Liabilities stands at $256.5 million for Q3 2020, versus $111.0 million for Q4 2019 and $110.0 million for Q3 2019.